Xvivo Perfusion Ab · OMXSTO:XVIVO
Xvivo Perfusion Ab — Q1 2023 Earnings Presentation
20 slides from Xvivo Perfusion Ab's earnings presentation, Apr 24, 2023
Slide 1: Interim report Q1 2023
Interim report Q1 2023 Earnings call, April 24, 2023 1
Slide 2: Today's presenters
Today’s presenters Christoffer Rosenblad, CEO Kristoffer Nordström, CFO
Slide 3: Q1 Financials – at a glance
Q1 Financials – at a glance Organic Growth Net Sales Thoracic Disposable sales SEK 141 Million • Net Sales • Gross margin SEK 91 million Disposables 86% +32% Sales growth Abdominal Disposable sales Total 52% • Net Sales SEK 31 million - Organic growth 34 % • Gross margin Disposables 65% +82% - Acqui
Slide 4: Q1 Highlights
Q1 Highlights 4
Slide 5: XVIVO Heart Preservation System
XVIVO Heart Preservation System Australia & New Zeeland off to a flying start Commercially • Compassionate use cases represented ~25% of all heart transplants in the region in Q1 • All 5 clinics participating in the study have continued to use the device after the trial Clinical data • Study data fe
Slide 6: Strong presence at ISHLT
Strong presence at ISHLT Machine perfusion remains in focus Highlights • XVIVO Heart Preservation System demonstrated for the first time with extensive interest from US transplantation clinics uniformly asking to be represented in coming clinical trial. • XVIVO arranged industry symposium focusing o
Slide 7: New publications indicate wide potential for XVIVO technologies
New publications indicate wide potential for XVIVO technologies • Liver Assist was featured in the NEJM1 in 2021 - showing that hypothermic oxygenated perfusion (HOPE) of DCD livers before transplantation has a significant positive impact on post- transplant clinical outcomes • In Q1, the Journal of
Slide 8: Clinical pipeline
Clinical pipeline 8
Slide 9: Status in clinical trials
Status in clinical trials European Heart preservation trial US Liver preservationTrial • All planned 15 centers active across 8 countries • Liver Assist granted Breakthrough Device • Approx. 95% of patients enrolled Designation by FDA • Trial design and planning phase Target: Commercial launch Q1 20
Slide 10: Financial Performance Q1
Financial Performance Q1 10
Slide 11: Net sales and results in Q1
Total Sales Net sales and results in Q1 growth 52% Jan-Mar Jan-Mar Full Year SEK Million 2023 2022 2022 Net sales 141 93 415 Sales growth, % 52 % 42% 61 % Whereof organic growth, % 34 % 32 % 30 % Gross profit 105 65 297 Gross margin, % 75 % 70 % 72 % EBIT (adj) 12 5 14 EBIT, % (adj) 9% 6% 3% EBITDA
Slide 12: Thoracic – Q1 Highlights
Thoracic – Q1 Highlights Net Sales Net sales by Net sales by product Net sales SEK 91 million (68) region category Organic growth in local currency 6% 2% 23 % (35 %) 26% Gross margin disposables 48% 50% 86 % (84) 10% 64% 94% XPS machines Americas Machine perfusion Machines Disposables delivered APAC
Slide 13: Abdominal – Q1 Highlights
Abdominal – Q1 Highlights Net Sales Net sales by Net sales by Net sales SEK 31 million (15) region product category Organic growth in local currency 3% 1% 15% 85 % (21) 0% Gross margin disposables 65 % (55) 85% 96% 100% Organic growth Americas Machine perfusion Machines Disposables disposables (%) A
Slide 14: Services – Q1 Highlights
Services –Q1 Highlights Recovery cases Q1 Net Sales Q1 Sales growth Q1 3 Net Sales (SEK) Sales growth Q1 56 146 87 19m 82% Hearts Lungs Heart-Lung block 14
Slide 15: EBITDA
EBITDA EBITDA (adj) Q1 18% EBITDA (adj), R12 months EBITDA (adj), by quarter SEKm SEKm 80 25,0% 30 25,0% Comments 22,5% 22,5% 70 66 25 20,0% 25 • R12 Trend continues with 20,0% 60 56 increased EBITDA 17,5% 20 17,5% 20 50 46 15,0% 15,0% • Primarily driven by increased 41 40 39 12,5% 15 15 12,5% gross
Slide 16: Financial position and cash flow (Mar 31, 2023)
Financial position and cash flow (Mar 31, 2023) Cash flow from Q1 financials Comments Q1 operating activities (SEK million) • Cash flow from operating • Cashflow affected changes in NWC activities SEK -12 million (-9) 50 • Cashflow from operating • Strong end of the quarter sales 40 impacts AR activ
Slide 17: Outlook
Outlook tet L _-
Slide 18: Long term outlook
Long term outlook • The demand for transplants are x 10 of today’s supply • Sales value of machine perfusion vs cold static storage is ~x 10 • Machine perfusion has proven to increase the number of organs used for transplantation • XVIVO has unique, innovative and world leading products on the marke
Slide 19: Outlook 2023
Outlook 2023 • Machine perfusion – continued momentum through hub and service models • Kidney Assist Transport – Launch in the US and Europe • Heart – Prepare for commercial launch Europe and ANZ. Start PMA trial in the US • Liver – Prepare for trial application submission in the US • Continued pric
Slide 20: Nobody should die waiting for a new organ
Our vision Nobody should die waiting for a new organ 20